Central States Research

Futó vizsgálatok

• Toboroz

  A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  NCT07794579· 3. fázis· Forrás

• Toboroz

  A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

  NCT07668336· 3. fázis· Forrás

• Toboroz

  Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

  NCT07353931· 3. fázis· Forrás

• Toboroz

  A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

  NCT07011732· 3. fázis· Forrás

• Toboroz

  A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine

  NCT06995729· 1. fázis· Forrás

• Fut, nem toboroz

  Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

  NCT06297603· 3. fázis· Forrás

• Fut, nem toboroz

  Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

  NCT06260722· 3. fázis· Forrás

• Meghívásos bevonás

  Alzheimer's Disease Neuroimaging Initiative 4

  NCT05617014· Forrás

• Fut, nem toboroz

  A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

  NCT05026866· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Alzheimer-kór2 toboroz
• Elhízás2 toboroz
• 2-es típusú cukorbetegség1 toboroz
• Frontotemporális demencia1 toboroz
• Migrén1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Visszavonták

  A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

  NCT06901349· 2. fázis· Forrás

• Lezárult

  A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

  NCT05803421· 3. fázis· Forrás

• Lezárult

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· 3. fázis· Forrás